TEBENTAFUSP for Malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 13 adverse event reports in the FDA FAERS database where TEBENTAFUSP was used for Malignant melanoma.
Most Reported Side Effects for TEBENTAFUSP
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Cytokine release syndrome | 35 | 35.7% | 12 | 22 |
| Pyrexia | 19 | 19.4% | 7 | 13 |
| Malignant neoplasm progression | 18 | 18.4% | 4 | 7 |
| Disease progression | 11 | 11.2% | 11 | 1 |
| Pruritus | 10 | 10.2% | 4 | 3 |
| Rash | 9 | 9.2% | 2 | 6 |
| Chills | 8 | 8.2% | 4 | 4 |
| Hypotension | 8 | 8.2% | 5 | 7 |
| Death | 7 | 7.1% | 7 | 0 |
| Vomiting | 7 | 7.1% | 5 | 5 |
| Diarrhoea | 5 | 5.1% | 3 | 4 |
| Fatigue | 5 | 5.1% | 0 | 5 |
| Oxygen saturation decreased | 5 | 5.1% | 3 | 4 |
Other Indications for TEBENTAFUSP
Uveal melanoma (33)
Product used for unknown indication (21)
Metastatic ocular melanoma (15)
Choroid melanoma (8)
Other Drugs Used for Malignant melanoma
NIVOLUMAB (10,599)
IPILIMUMAB (8,903)
DABRAFENIB (5,277)
TRAMETINIB DIMETHYL SULFOXIDE (3,841)
PEMBROLIZUMAB (3,261)
BINIMETINIB (2,613)
ENCORAFENIB (2,591)
VEMURAFENIB (2,548)
TRAMETINIB (1,448)
COBIMETINIB (1,324)